Home Technology 3D Systems Climbs Despite Setback

3D Systems Climbs Despite Setback

When you purchase through our sponsored links, we may earn a commission. By using this website you agree to our T&Cs.

Gulf Coast Ultra Deep Royalty Trust (NASDAQ:GULTU), MacroGenics Inc (NASDAQ:MGNX) and 3D Systems Corporation (NYSE:DDD) are making notable gains this Friday. Posting losses today are Bio Blast Pharma Ltd (NASDAQ:ORPN), Tasman Metals Ltd (NYSEMKT:TAS) and Novacopper Inc (NYSEMKT:NCQ).

Sign up for our free daily newsletter

MicroGenics Inc. Continues to Climb

Gulf Coast Ultra Deep Royalty Trust (NASDAQ:GULTU) climbed +23.69% early in the day in the wake of news of a successful production test from Freeport-McMoRan Oil & Gas’ Highlander discovery. GULTU’s surge gives a boost to the investment portfolios of billionaire shareholders Leon Cooperman and John Paulson.


MacroGenics Inc (NASDAQ:MGNX) rallied +8.45% today, putting its one-month gain at +27.71%. The biopharmaceutical company inked a major deal with Johnson & Johnson on the 22nd. George Soros picked up a position in MacroGenics in the second quarter of the year and as of the third quarter holds 19,000 MGNX shares.

3D Systems Corporation (NYSE:DDD) gained +7.73% today despite suffering a major setback with Google’s comments that it won’t use 3D-printed materials for Project Ara. In the Tiger Global portfolio since 2012, DDD has struggled on the market this year, its price declining -64.87% year-to-date.

Soros Picks Bio Blast, Tasman Metals Tumble

Bio Blast Pharma Ltd (NASDAQ:ORPN) dipped -7.36% early in the day this Friday. The biotech company is a new third quarter acquisition for billionaire George Soros, who during the period purchased 71,000 ORPN shares.

Tasman Metals Ltd (NYSEMKT:TAS) tumbled -6.47% today, putting its YTD loss at -55.15%. The junior resource company is a long-time Soros investment.

Also in the red today is Novacopper Inc (NYSEMKT:NCQ), down -5.61%. The base metals exploration company has been in John Paulson’s portfolio since the second quarter of 2012. Its price has declined -65.79% year-to-date and -18.75% over the past month.


Our Editorial Standards

At ValueWalk, we’re committed to providing accurate, research-backed information. Our editors go above and beyond to ensure our content is trustworthy and transparent.


Want Financial Guidance Sent Straight to You?

  • Pop your email in the box, and you'll receive bi-weekly emails from ValueWalk.
  • We never send spam — only the latest financial news and guides to help you take charge of your financial future.